- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03211195
Sotagliflozin Bioequivalence Study
Bioequivalence Study Comparing Sotagliflozin Tablet Commercial Formulation (Test) and Sotagliflozin Tablet Development Formulation (Reference) in Healthy Male and Female Subjects Under Fasted Conditions
Primary Objective:
To determine the bioequivalence of a single dose of the commercial tablet of sotagliflozin (test) compared to the development tablet of sotagliflozin (reference) under fasting conditions in healthy male and female subjects.
Secondary Objectives:
- To evaluate the single-dose pharmacokinetics of sotagliflozin and its main metabolite sotagliflozin 3-O-glucuronide following administration of a single sotagliflozin (test) tablet or a single sotagliflozin (reference) table in healthy male and female subjects under fasting conditions.
- To evaluate safety and tolerability of a single dose sotagliflozin (test) tablet compared to a single sotagliflozin (reference) tablet administered under fasted conditions in healthy male and female subjects.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33014
- Investigational Site Number 840001
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria :
- Healthy male and female subjects 18-55 years old inclusive, male or female.
- Certified as healthy by comprehensive clinical assessment (detailed medical history and complete physical examination).
- Body weight between 50.0 and 100.0 kg, inclusive if male, and between 40.0 and 90.0 kg, inclusive if female, Body mass index (BMI) of 18.0 to 30.0 kg/m2 inclusive.
- Normal vital signs, ECG and laboratory parameters.
- Female subjects must use a double contraception method including a highly effective method of contraception except if she has undergone sterilization at least 3 months earlier or is post-menopausal. Hormonal contraception is permitted in this study.
- Having given written informed consent prior to undertaking of study procedure.
- Covered by a health insurance system where applicable, and/or in compliance with the recommendation of the national laws in force relating to biomedical research.
- Not under any administrative or legal supervision.
- Male subjects, whose partners are of childbearing potential (including lactating women) must accept to use, during sexual intercourse, a double contraception method from the inclusion up to 3 months after the last dosing.
- Male subjects, who partners are pregnant, must use during sexual intercourse a condom from inclusion to three months after the last dosing.
- Male subject has agreed not to donate sperm from the time of inclusion up to 3 months after the last dosing.
Exclusion criteria:
- Any history or presence of clinically relevant disease at screening which could interfere with the objectives of the study or the safety fo the subject's participation.
- History of renal disease, or significantly abnormal kidney function test (glomerular filtration rate [GFR]<90 mg/min as calculated using the Cockcroft-Gault equation) at screening.
- Frequent headaches and/or migraines, recurrent nausea and/or vomiting.
- Blood donation of a pint or more within 2 months before inclusion.
- Symptomatic, postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood pressure of 20 mmHg or more within 3 minutes when changing from supine to standing position.
- Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician.
- Any history of presence of deep vein thrombosis or pulmonary embolism or a recurrent or frequent history of deep vein thrombosis in first degree relatives (parents, siblings, or children).
- Any presence or history of urinary tract infection or genital mycotic infection in the last 4 weeks before screening.
- History or presence of drug or alcohol abuse.
- Smoking more than 5 cigarettes or equivalent per day, unable to stop smoking during the study.
- Excessive consumption of beverages containing xanthine bases (more than 4 cups or glasses per day).
- If female, pregnancy (defined as positive beta-HCG) blood test if applicable) breast-feeding.
- Any medication (including St John's Wort) within 14 days before inclusion or within 5 time the elimination half-life or pharmacodynamic half-life of the medication; any vaccination within the last 28 days and any biologics (antibody or its derivatives) given within 4 months before inclusion or within 5 terminal elimination half-life of the biologic.
- Any subject in the exclusion period of a previous study according to applicable regulations.
- Any subject who cannot be contracted in the case of an emergency.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Sotagliflozin - Commerical
Healthy volunteers will be administered a single dose Sotagliflozin (SAR439954) tablet (Commercial formulation) by mouth under fasted conditions
|
Pharmaceutical form: tablet Route of administration: oral |
ACTIVE_COMPARATOR: Sotagliflozin -Development
Healthy volunteers will be administered a single dose Sotagliflozin (SAR439954) tablet (Development formulation) by mouth under fasted conditions - Type: Active Comparator
|
Pharmaceutical form: tablet Route of administration: oral |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of PK (pharmacokinetic) parameter: Cmax
Time Frame: From 0 to 120 hours after SAR439954 intake
|
Sotagliflozin: Maximum plasma concentration (Cmax)
|
From 0 to 120 hours after SAR439954 intake
|
Assessment of PK parameter: AUClast
Time Frame: From 0 to 120 hours after SAR439954 intake
|
Sotagliflozin: Area under the concentration-time curve from 0 to last quantifiable concentration (AUClast)
|
From 0 to 120 hours after SAR439954 intake
|
Assessment of PK parameter: AUC
Time Frame: From 0 to 120 hours after SAR439954 intake
|
Sotagliflozin: Area under the concentration-time curve from 0 to infinity
|
From 0 to 120 hours after SAR439954 intake
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of PK parameter: Tmax
Time Frame: From 0 to 120 hours after SAR439954 intake
|
Sotagliflozin: Time to reach maximum plasma concentration (Tmax)
|
From 0 to 120 hours after SAR439954 intake
|
Assessment of PK parameter: t1/2
Time Frame: From 0 to 120 hours after SAR439954 intake
|
Sotagliflozin: Terminal elimination half life (T1/2)
|
From 0 to 120 hours after SAR439954 intake
|
Assessment of PK parameter: Vz/F
Time Frame: From 0 to 120 hours after SAR439954 intake
|
Sotagliflozin: Apparent volume of distribution during terminal phase after non-intravenous administration Vz/F
|
From 0 to 120 hours after SAR439954 intake
|
Assessment of PK parameter: CL/F
Time Frame: From 0 to 120 hours after SAR439954 intake
|
Sotagliflozin: Apparent total body clearance of a drug from the plasma (CL/F)
|
From 0 to 120 hours after SAR439954 intake
|
Assessment of PK parameter: Cmax
Time Frame: From 0 to 120 hours after SAR439954 intake
|
Sotagliflozin 3-O-glucuronide: Maximum plasma concentration (Cmax)
|
From 0 to 120 hours after SAR439954 intake
|
Assessment of PK parameter: AUC
Time Frame: From 0 to 120 hours after SAR439954 intake
|
Sotagliflozin 3-O-glucuronide: Area under the concentration-time curve from 0 to infinity
|
From 0 to 120 hours after SAR439954 intake
|
Assessment of PK parameter: AUClast
Time Frame: From 0 to 120 hours after SAR439954 intake
|
Sotagliflozin 3-O-glucuronide: Area under the concentration-time curve from 0 to last quantifiable concentration (AUClast)
|
From 0 to 120 hours after SAR439954 intake
|
Assessment of PK parameter: Tmax
Time Frame: From 0 to 120 hours after SAR439954 intake
|
Sotagliflozin 3-O-glucuronide: Time to reach maximum plasma concentration (Cmax)
|
From 0 to 120 hours after SAR439954 intake
|
Assessment of PK parameter: t1/2
Time Frame: From 0 to 120 hours after SAR439954 intake
|
Sotagliflozin 3-O-glucuronide: Terminal elimination half life (T1/2)
|
From 0 to 120 hours after SAR439954 intake
|
Treatment emergent adverse events (TEAE)
Time Frame: From 0 to 144 hours after SAR439954 intake
|
Number treatment emergent adverse events
|
From 0 to 144 hours after SAR439954 intake
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Sodium-Glucose Transporter 2 Inhibitors
- (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
Other Study ID Numbers
- BEQ15271
- U1111-1197-7610 (OTHER: UTN)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
Clinical Trials on Sotagliflozin (SAR439954)
-
SanofiCompleted
-
Lexicon PharmaceuticalsSanofiCompletedType 2 Diabetes MellitusUnited States, Canada, Mexico
-
Lexicon PharmaceuticalsSanofiTerminatedCardiac Failure AggravatedUnited States, Canada, Netherlands
-
Lexicon PharmaceuticalsSanofiTerminatedHeart Failure | Chronic Kidney Diseases | Type 2 Diabetes MellitusEstonia, Belgium, Sweden, Italy, China, United States, Canada, Bulgaria, Chile, Denmark, Hungary, Latvia, Mexico, Russian Federation, Serbia, Spain, Portugal, Romania, Turkey, Poland, Lithuania, Argentina, Australia, Brazil, Czechia, France, Georg... and more
-
Lexicon PharmaceuticalsSanofiTerminatedHeart Failure | Type 2 Diabetes MellitusBelgium, Canada, Israel, Spain, Germany, Argentina, Chile, Hungary, Korea, Republic of, Latvia, Lithuania, Russian Federation, Sweden, Romania, Poland, Brazil, Denmark, United States, Australia, Austria, Czechia, Finland, France, Greece, Ita... and more
-
SanofiCompletedType 2 Diabetes Mellitus | Healthy SubjectsUnited States
-
SanofiCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusGermany
-
Lexicon PharmaceuticalsSanofiCompletedType 2 Diabetes Mellitus | Chronic Kidney Disease Stage 3United States, Argentina, Brazil, Canada, Colombia, Germany, Hungary, Israel, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine
-
SanofiCompleted
-
Lexicon PharmaceuticalsSanofiCompletedType 2 Diabetes Mellitus | Chronic Kidney Disease Stage 4United States, Argentina, Brazil, Colombia, Germany, Hungary, Israel, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine